That creates a simple problem for manufacturers. A security flaw may not stop at data exposure. If someone can interfere with software, communications, or device settings, the effect can reach the device’s clinical function and, in some cases, patient safety.
The MHRA has already acknowledged these risks in networked medical devices, including tampering, malfunction, data loss, equipment damage, and possible injury. As products become more connected, MHRA medical device guidance is placing greater weight on software safety and cybersecurity.
Finding serious weaknesses late can mean more fixes, more validation work, and weaker evidence at the point of regulatory review.
Penetration testing gives manufacturers a way to identify weaknesses before they become harder and more expensive to address.
The UK Medical Devices Regulations 2002
Medical devices placed on the Great Britain market are regulated under the Medical Devices Regulations 2002, as amended. Great Britain covers England, Scotland, and Wales. Northern Ireland follows a different framework that applies EU medical device rules. 7
Under the UK Medical Devices Regulations, manufacturers must meet the applicable safety and performance requirements. Cybersecurity becomes relevant when a weakness could interfere with a device’s intended function or contribute to patient or user harm.
How Cybersecurity Can Become a Patient Safety Risk
The safety concern starts when a weakness gives someone a way to interfere with the device. From there, the question is whether that interference can change what the device does in a clinically meaningful way and put the patient at risk.
For example, if a connected infusion system has an API that fails to properly authorise treatment changes, an attacker could alter a therapy parameter. If the device accepts that change, treatment delivery may be affected, and the patient could receive inappropriate therapy.
For medical device cybersecurity compliance, the important question is not only how severe a vulnerability appears technically. Manufacturers also need to determine whether exploitation could affect clinical behaviour, confidentiality, or safe operation.
Source: https://qualysec.com/mhra-m ...